Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
8,396,793
-
Share change
-
+85,499
-
Total reported value
-
$32,140,271
-
Put/Call ratio
-
133%
-
Price per share
-
$3.83
-
Number of holders
-
69
-
Value change
-
-$25,813
-
Number of buys
-
33
-
Number of sells
-
44
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q1 2021
As of 31 Mar 2021,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,396,793 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, JPMORGAN CHASE & CO, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, Ikarian Capital, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, ABNER HERRMAN & BROCK LLC, and RAYMOND JAMES & ASSOCIATES.
This page lists
69
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.